Table 3 Patient characteristics and surgical data by postoperative left ventricular reverse remodeling in the mitral annuloplasty group

Clinical data

 Age, years

63 ± 9

64 ± 9

0.64

 Male sex

18 (72%)

16 (73%)

0.96

 Medical history and presentation at baseline

  NYHA functional class III or IV

21 (84%)

22 (100%)

0.020

  Logistic EuroSCORE II

4.3 [2.6, 8.5]

8.0 [5.3, 13.5]

0.007

  Chronic kidney disease stage 4 or 5

7 (28%)

9 (41%)

0.35

  Atrial fibrillation

18 (72%)

6 (27%)

0.002

  Diabetes mellitus

5 (20%)

8 (36%)

0.21

  Hypertension

8 (32%)

4 (18%)

0.27

  Previous CRT

2 (8%)

7 (32%)

0.035

 Medication at baseline

  Beta-blocker

18 (72%)

17 (72%)

0.68

  ACE inhibitor or angiotensin-receptor blocker

15 (60%)

12 (55%)

0.71

  Diuretic

21 (84%)

19 (86%)

0.82

Echocardiography

 LV end-diastolic dimension, mm

67 ± 10

73 ± 10

0.039

 LV end-systolic dimension, mm

58 ± 10

65 ± 11

0.018

 LV end-diastolic volume index, ml/m²

147 ± 50

179 ± 50

0.033

 LV end-systolic volume index, ml/m²

107 ± 43

141 ± 47

0.013

 LV ejection fraction, %

29 ± 8

25 ± 8

0.065

 Left atrial dimension, mm

50 ± 8

48 ± 9

0.33

 Mitral regurgitation grade

0.49

  Moderate

10 (40%)

11 (50%)

  Severe

15 (60%)

11 (50%)

 Tricuspid regurgitation grade

0.11

  Mild

11 (44%)

9 (41%)

  Moderate

9 (36%)

5 (23%)

  Severe

3 (12%)

2 (9%)

Surgical data

 Papillary muscle approximation

11 (44%)

11 (50%)

0.68

 Concomitant procedures

 Tricuspid valve repair

20 (80%)

13 (59%)

0.12

 Atrial maze

10 (40%)

6 (27%)

0.36